Phase I Trial of IDH1 Peptide Vaccine in IDH1R132H-mutated Grade III-IV Gliomas

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

September 19, 2017

Study Completion Date

September 19, 2017

Conditions
Glioma
Interventions
DRUG

IDH1 peptide vaccine

Trial Locations (8)

Unknown

Charité Berlin, Neurosurgery, Berlin

University Hospital Dresden, Neurosurgery, Dresden

University Hospital Essen, Internal Medicine, Essen

University Hospital Frankfurt, Neurooncology, Frankfurt am Main

University Hospital Freiburg, Neurosurgery, Freiburg im Breisgau

University Hospital Heidelberg, Neurology Clinic, Heidelberg

LMU, University Hospital Munich, Munich

University Hospital Tuebingen, Neurooncology, Tübingen

All Listed Sponsors
collaborator

University Hospital Heidelberg

OTHER

collaborator

German Cancer Research Center

OTHER

collaborator

Neuro-Oncology Working Group of the German Cancer Society

NETWORK

lead

National Center for Tumor Diseases, Heidelberg

OTHER

NCT02454634 - Phase I Trial of IDH1 Peptide Vaccine in IDH1R132H-mutated Grade III-IV Gliomas | Biotech Hunter | Biotech Hunter